Angiogenesis is a well-recognized hallmark of cancer, critically involved in tumor growth and metastatic spread. One of the key players in tumor-induced angiogenesis is VEGF-A, which is often found upregulated in many solid tumors. Bevacizumab is a humanized monoclonal antibody, whose mechanism of action is to target and neutralize human VEGF-A. Currently, bevacizumab is used in the clinic as a single agent or combined with antineoplastic drugs for several advanced cancers.
